COVID-19 vaccines and dermatologic diseases

a real-world observational study of immunogenicity of COVID-19 vaccines among patients with immune-mediated dermatologic diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220317008

Enrollment

300

Registered

2022-03-17

Start date

2021-06-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immune-mediated dermatologic diseases COVID-19 vaccine immunogenicity COVID-19 vaccine safety COVID-19 vaccines CoronaVac inactivated SARS-CoV-2 vaccines Vaxzevria ChAdOx1-S [recombinant] immune-mediated dermatologic diseases psoriasis autoimmune bullous diseases

Interventions

Participants with any immune-mediated dermatologic diseases who was diagnosed and had been followed-up by dermatologist.,Participants without dermatologic or systemic immune-mediated conditions.

Basic Science,Basic Science

Participants with any immune-mediated dermatologic diseases ,Participants without immune-mediated conditions.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients visited Ramathibodi hospital's dermatology outpatient department 2. aged >= 18 years old 3. Had not received COVID19 vaccines 4. Had a scheduled date for COVID19 vaccination

Exclusion criteria

Exclusion criteria: 1. Immune-mediated dermatologic disease patients with uncontrolled disease activity 2. pre-existing HIV infection 3. cancer 4. non-dermatologic immune-mediated diseases 5. history of previous COVID-19 infection 6. tested positive for anti-SARS-CoV-2 IgG before vaccination.

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 specific humoral immunity 28 days post-vaccination anti-SARS-CoV-2 S1 RBD IgG ,SARS-CoV-2 specific humoral immunity 28 days post-vaccination SARS-CoV-2 surrogate neutralising antibodies ,SARS-CoV-2 specific cellular immunity 28 days post-vaccination SARS-CoV-2 interferon-gamma releasing assay	—

Secondary

Measure	Time frame
discordant humoral-cellular immune response 28 days post-vaccination the percentages of participants with discordant humoral-cellular immune response,vaccine-related adverse reactions 28 days post-vaccination the percentages of participants reported adverse reactions (unsolicited),disease activity 28 days post-vaccination the percentages of participants who need to increase the dose of immunosuppressants during vaccination	—

Measure

Time frame

discordant humoral-cellular immune response 28 days post-vaccination the percentages of participants with discordant humoral-cellular immune response,vaccine-related adverse reactions 28 days post-vaccination the percentages of participants reported adverse reactions (unsolicited),disease activity 28 days post-vaccination the percentages of participants who need to increase the dose of immunosuppressants during vaccination

—

Countries

Thailand

Contacts

Public ContactPoonkiat Suchonwanit

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University

czircons@gmail.com0641569654

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026